Home › Minerva Biotechnologies Licenses Sendai Virus Technology For Stem Cell Generation
 

Keywords :   


Minerva Biotechnologies Licenses Sendai Virus Technology For Stem Cell Generation

2015-09-02 07:10:05| drugdiscoveryonline News Articles

Minerva Biotechnologies and ID Pharma Co., Ltd. (formerly DNAVEC) announced recently that they have signed an agreement granting Minerva worldwide rights to use and commercialize their non-integrating Sendai virus vectors, together with Minerva’s proprietary technology, for generating Induced Pluripotent Stem (iPS) cells

Tags: technology cell generation virus

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
20.09Labelexpo Americas highlights, Maxcess announces acquisition and more
20.09September Cattle on Feed as expected
20.09USDA announces major investment in meat and poultry processing
20.09Atlantic Tropical Weather Outlook
20.09Eastern North Pacific Tropical Weather Outlook
20.09This weeks lesson: Weaning matters in the cattle market
More »